Jump to Main Contents
研究所ロゴ

Home > Organization > Divisions and Independent Research Units > Division of Rare Cancer > Research Papers (249 papers)

Research Papers (249 papers)

2024

  1. Ono T, Kodera Y, Kondo T. Data for proteomic analysis of sarcoma spheroids cultured with perfusion and without perfusion. Journal of Proteome Data and Methods. 2024 Mar. accepted.
  2. Adachi Y, Noguchi R, Yoshimatsu Y, Sin Y, Osaki J, Ono T, Iwata S, Akiyama T, Tsuchiya R, Toda Y, Ishihara S, Ogura K, Kobayashi E, Kojima N, Yoshida A, Yokoo H, Kawai A, Kondo T. Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone: NCC-GCTB8-C1 and NCC-GCTB9-C1. Hum Cell. 2024 Feb. PMID: 38466561. DOI: 10.1007/s13577-024-01042-5 [PubMed] (external link)
  3. Osaki J, Noguchi R, Yanagihara K, Ono T, Adachi Y, Iwata S, Toda Y, Sekita T, Kobayashi E, Kojima N, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-ASPS2-C1: a novel patient-derived cell line of alveolar soft part sarcoma. Hum Cell. 2024 Mar 13. doi: 10.1007/s13577-024-01039-0. Epub ahead of print. PMID: 38478355. [PubMed] (external link)
  4. Ono T, Noguchi R, Osaki J, Akiyama T, Adachi Y, Kojima N, Toda Y, Fukushima S, Yoshimatsu Y, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-DFSP5-C1: a novel patient-derived dermatofibrosarcoma protuberans cell line. Hum Cell. 2024 Feb 19. doi: 10.1007/s13577-024-01030-9. Epub ahead of print. PMID: 38372888. [PubMed] (external link)
  5. Takane K, Cai T, Noguchi R, Gohda Y, Ikenoue T, Yamaguchi K, Ota Y, Kiyomatsu T, Yano H, Fukuyo M, Seki M, Rahmutulla B, Kaneda A, Furukawa Y.  Genome-wide analysis of DNA methylation in pseudomyxoma peritonei originated from appendiceal neoplasms. Oncology. 2024;102(8):720-731.
     doi: 10.1159/000536219. PMID: 38262376. [PubMed] (external link）
  6. Osaki J, Noguchi R, Ono T, Adachi Y, Iwata S, Toda Y, Funada T, Iwata S, Kojima N, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-SS6-C1: a novel patient-derived cell line of synovial sarcoma. Hum Cell. 2024 Aug 23. doi: 10.1007/s13577-024-01122-6. Epub ahead of print. PMID: 39174825.  [PubMed] (external link)
  7. Adachi Y, Noguchi R, Osaki J, Ono T, Iwata S, Akiyama T, Tsuchiya R, Toda Y, Sekita T, Iwata S, Kobayashi E, Kojima N, Yoshida A, Yokoo H, Kawai A, Kondo T. Establishment and characterization of two novel patient-derived cell lines from myxofibrosarcoma: NCC-MFS7-C1 and NCC-MFS8-C1. Hum Cell. 2024. PMID: 39214957. DOI:10.1007/s13577-024-01124-4. [PubMed](external link)
  8. Noguchi R, Osaki J, Ono T, Adachi Y, Iwata S, Yoshimatsu Y, Sasaki K, Kawai A, Kondo T. Pharmacoproteogenomic Approach Identifies On-Target Kinase Inhibitors for Cancer Drug Repositioning. In Vitro Cellular & Developmental Biology - Animal. 2024 Sep 1. accepted.
  9. Ono T, Ono Y, Kondo T. Proteome analysis of murine organs using Auto2D. J Electrophoresis 68 (1):7-13. DOI:10.2198/jelectroph.68.7

2023

  1. Ono T, Kondo T. Data of distinct stromal protein expressions between sarcoma patient-derived models and their primary tumors. Journal of Proteome Data and Methods. in press.
  2. Isoyama S, Tamaki N, Noguchi Y, Okamura M, Yoshimatsu Y, Kondo T, Suzuki T, Yaguchi S, Dan S. Subtype-selective induction of apoptosis in translocation-related sarcoma cells induced by PUMA and BIM upon treatment with pan-PI3K inhibitors. Cell Death Dis. 2023 Feb;14,169. doi: https://doi.org/10.1038/s41419-023-05690-7. [Nature] (external link)
  3. Akiyama T, Yoshimatsu Y, Noguchi R, Sin Y, Osaki J, Ono T, Adachi Y, Tsuchiya R, Toda Y, Kobayashi E, Kojima N, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-DSM1-C1: a novel cell line derived from a patient with desmoid fibromatosis. Hum Cell. 2023 Mar;36(2):847-853. doi:10.1007/s13577-022-00850-x. Epub 2023 Jan 11. PMID: 36629983. [PubMed] (external link)
  4. Noguchi R, Yoshimura A, Uchino J, Takeda T, Chihara Y, Ota T, Hiranuma O, Gyotoku H, Takayama K, Kondo T. Comprehensive Kinase Activity Profiling Revealed the Kinase Activity Patterns Associated with the Effects of EGFR Tyrosine Kinase Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients with Sensitizing EGFR Mutations. Proteomes 2023, 11(1), 6; https://doi.org/10.3390/proteomes11010006. [MDPI]（external link）
  5. Akiyama T, Yoshimatsu Y, Noguchi R, Sin Y, Osaki J, Adachi Y, Ono T, Tsuchiya R, Sato C, Iwata S, Kojima N, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-PLPS2-C1: a novel cell line of pleomorphic liposarcoma. Hum Cell. 2023 Jan;36(1):468-475. doi:10.1007/s13577-022-00828-9. Epub 2022 Nov 27. PMID: 36436139. [PubMed] (external link)
  6. Akiyama T, Yoshimatsu Y, Noguchi R, Sin Y, Osaki J, Ono T, Adachi Y, Tsuchiya R, Toda Y, Ogura K, Kojima N, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-DFSP4-C1: a novel cell line from a patient with dermatofibrosarcoma protuberans having the fibrosarcomatous transformation. Hum Cell. 2023 Jul 25. doi: 10.1007/s13577-023-00932-4. Epub ahead of print. PMID: 37490236. [PubMed] (external link)
  7. Ono T, Noguchi R, Yoshimatsu Y, Sin Y, Tsuchiya R, Akiyama T, Kojima N, Toda Y, Sato C, Fukushima S, Yoshida A, Kawai A, Kondo T. Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone. Hum Cell. 2023 Jun 17. doi: 10.1007/s13577-023-00928-0. Epub ahead of print. PMID: 37328637. [PubMed] (external link)
  8. Tsuchiya R, Yoshimatsu Y, Noguchi R, Sin Y, Ono T, Akiyama T, Kosako H, Yoshida A, Ohtori S, Kawai A, Kondo T. Integrating analysis of proteome profile and drug screening identifies therapeutic potential of MET pathway for the treatment of malignant peripheral nerve sheath tumor. Expert Rev Proteomics. 2023 May 29:1-11. doi: 10.1080/14789450.2023.2218035. PMID: 37229542. [PubMed] (external link)
  9. Noguchi R, Kosako H, Sasaki K, Kondo T. Data for proteogenomic analysis of two patient-derived undifferentiated pleomorphic sarcoma cell lines. Journal of Proteome Data and Methods. 2023 June;5. doi: https://doi.org/10.14889/jpdm.2023.0013. [J-STAGE] (external link)
  10. Ono T, Kondo T. Data of distinct stromal protein expressions between sarcoma patient-derived models and their primary tumors. Journal of Proteome Data and Methods. 2023 Apr;5. doi: https://doi.org/10.14889/jpdm.2023.0011.  [J-STAGE] (external link)
  11. Isoyama S, Tamaki N, Noguchi Y, Okamura M, Yoshimatsu Y, Kondo T, Suzuki T, Yaguchi S, Dan S. Subtype-selective induction of apoptosis in translocation-related sarcoma cells induced by PUMA and BIM upon treatment with pan-PI3K inhibitors. Cell Death Dis. 2023 Feb;14,169. doi: https://doi.org/10.1038/s41419-023-05690-7. [Nature] (external link)
  12. Akiyama T, Yoshimatsu Y, Noguchi R, Sin Y, Osaki J, Ono T, Adachi Y, Tsuchiya R, Toda Y, Kobayashi E, Kojima N, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-DSM1-C1: a novel cell line derived from a patient with desmoid fibromatosis. Hum Cell. 2023 Mar;36(2):847-853. doi:10.1007/s13577-022-00850-x. Epub 2023 Jan 11. PMID: 36629983. [PubMed] (external link)
  13. Noguchi R, Yoshimura A, Uchino J, Takeda T, Chihara Y, Ota T, Hiranuma O, Gyotoku H, Takayama K, Kondo T. Comprehensive Kinase Activity Profiling Revealed the Kinase Activity Patterns Associated with the Effects of EGFR Tyrosine Kinase Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients with Sensitizing EGFR Mutations. Proteomes 2023, 11(1), 6; https://doi.org/10.3390/proteomes11010006.  [MDPI] (external link)
  14. Akiyama T, Yoshimatsu Y, Noguchi R, Sin Y, Osaki J, Adachi Y, Ono T, Tsuchiya R, Sato C, Iwata S, Kojima N, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-PLPS2-C1: a novel cell line of pleomorphic liposarcoma. Hum Cell. 2023 Jan;36(1):468-475. doi:10.1007/s13577-022-00828-9. Epub 2022 Nov 27. PMID: 36436139. [PubMed] (external link)
  15. Amada K, Hijiya N, Ikarimoto S, Yanagihara K, Hanada T, Hidano S, Kurogi S, Tsukamoto Y, Nakada C, Kinoshita K, Hirashita Y, Uchida T, Shin T, Yada K, Hirashita T, Kobayashi T, Murakami K, Inomata M, Shirao K, Aoki M, Takekawa M, Moriyama M. Involvement of clusterin expression in the refractory response of pancreatic cancer cells to a MEK inhibitor. Cancer Sci. 2023 May;114(5):2189-2202. doi: 10.1111/cas.15735. Epub 2023 Feb 9. PMID: 36694355; PMCID: PMC10154874. [PubMed] (external link)

2022

  1. Akiyama T, Yoshimatsu Y, Noguchi R, Sin Y, Tsuchiya R, Ono T, Sugaya J, Kobayashi E, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-PS1-C1: a novel cell line of pleomorphic sarcoma from a patient after neoadjuvant radiotherapy. Hum Cell. 2022 Nov;35(6):2011-2019. doi: 10.1007/s13577-022-00787-1. Epub 2022 Sep 14. PMID: 36103079. [PubMed] (external link)
  2. Akiyama T, Yoshimatsu Y, Noguchi R, Sin Y, Tsuchiya R, Ono T, Sato C, Kojima, N, Yoshida A, Kawai A, Ohtori S, Kondo T. Establishment and characterization of NCC-MRT1-C1: a novel cell line of malignant rhabdoid tumor. Hum Cell. 2022, Nov;35(6):2002-2010. doi: 10.1007/s13577-022-00751-z. Epub 2022 Aug 5. Erratum in: Hum Cell. 2022 Oct 18;: PMID: 35927606. [PubMed] (external link)
  3. Yoshimatsu Y, Noguchi R, Sin Y, Tsuchiya R, Ono T, Akiyama T, Sato C, Kobayashi E, Kojima N, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-MFS6-C1: a novel patient-derived cell line of myxofibrosarcoma. Hum Cell. 2022 Nov;35(6):1993-2001. doi: 10.1007/s13577-022-00749-7. Epub 2022 Aug 10. PMID: 35947340. [Pubmed] (external link)
  4. Akiyama T, Yoshimatsu Y, Noguchi R, Sin Y, Tsuchiya R, Ono T, Fukushima S, Toda Y, Kojima N, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-GCTB5-C1: a novel cell line of giant cell tumor of bone. Hum Cell. 2022 Jun 2. doi: 10.1007/s13577-022-00724-2. Epub ahead of print. PMID: 35653034. [PubMed]（external link）
  5. Yoshimatsu Y, Noguchi R, Sin Y, Tsuchiya R, Ono T, Akiyama T, Sugaya J, Kojima N, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-SS5-C1: a novel patient-derived cell line of synovial sarcoma. Hum Cell. 2022 Jul;35(4):1290-1297. doi: 10.1007/s13577-022-00721-5. Epub 2022 Jun 2. PMID: 35655041. [PubMed]（external link）
  6. Noguchi R, Yoshimatsu Y, Sin Y, Tsuchiya R, Ono T, Akiyama T, Hirabayashi K, Ozawa I, Nakagawa R, Kikuta K, Kondo T. Establishment and characterization of two novel patient-derived myxoid liposarcoma cell lines. Hum Cell. 2022 Jul;35(4):1279-1289. doi: 10.1007/s13577-022-00717-1. Epub 2022 May 30. PMID: 35637403. [PubMed]（external link）
  7. Yoshimatsu Y, Noguchi R, Sin Y, Tsuchiya R, Ono T, Akiyama T, Nakagawa R, Kamio S, Hirabayashi K, Ozawa I, Kikuta K, Kondo T. Establishment and characterization of a novel patient-derived cell line of dedifferentiated liposarcoma, NCC-DDLPS6-C1. Hum Cell. 2022 Jul;35(4):1270-1278. doi: 10.1007/s13577-022-00710-8. Epub 2022 May 23. PMID: 35604485. [PubMed]（external link）
  8. Paudel D, Kuramitsu Y, Uehara O, Morikawa T, Yoshida K, Giri S, Islam ST, Kitagawa T, Kondo T, Sasaki K, Matsuoka H, Miura H, Abiko Y. Proteomic and microbiota analyses of the oral cavity during psychological stress. PLoS One. 2022 May 25;17(5):e0268155. doi: 10.1371/journal.pone.0268155. PMID: 35613108; PMCID: PMC9132284. [PubMed] (external link)
  9. Sin Y, Ono T, Tsuchiya R, Noguchi R, Yoshimatsu Y, Kosako H, Kondo T. Proteomic analysis of spheroids of rhabdomyosarcoma cells cultured with decellularized muscle extracts. J Electrophoresis. 2022:66:1-4. [J-Stage]（external link）
  10. Yoshimatsu Y, Noguchi R, Sin Y, Tsuchiya R, Ono T, Akiyama T, Nakagawa R, Kamio S, Hirabayashi K, Ozawa I, Kikuta K, Kondo T. Establishment and characterization of a novel patient-derived Ewing sarcoma cell line, NCC-ES2-C1. Hum Cell. 2022 Jul;35(4):1262-1269. doi: 10.1007/s13577-022-00701-9. Epub 2022 Apr 19. PMID: 35441357. [PubMed] (external link)
  11. Shirakihara T, Yamaguchi H, Kondo T, Yashiro M, Sakai R. Transferrin receptor 1 promotes the fibroblast growth factor receptor-mediated oncogenic potential of diffused-type gastric cancer. Oncogene. 2022 Mar 25. doi: 10.1038/s41388-022-02270-5. Epub ahead of print. PMID: 35338344. [PubMed]（external link）
  12. Ponce RKM, Thomas NJ, Bui NQ, Kondo T, Okimoto RA. WEE1 kinase is a therapeutic vulnerability in CIC-DUX4 undifferentiated sarcoma. JCI Insight. 2022 Mar 22;7(6):e152293. doi: 10.1172/jci.insight.152293. PMID: 35315355. [PubMed]（external link）
  13. Sin Y, Yoshimatsu Y, Noguchi R, Tsuchiya R, Ono T, Akiyama T, Iwata S, Sugaya J, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-DDLPS5-C1: a novel patient-derived cell line of dedifferentiated liposarcoma. Hum Cell. 2022 Mar 15. doi: 10.1007/s13577-022-00689-2. Epub ahead of print. PMID: 35292923. [PubMed]（external link）
  14. Noguchi R, Yoshimatsu Y, Sin Y, Ono T, Tsuchiya R, Yoshida A, Kiyono T, Yonemura Y, Kondo T. Establishment and characterization of NCC-PMP1-C1: a novel patient-derived cell line of metastatic pseudomyxoma peritonei. Pers. Med. 2022, 12(2), 258; https://doi.org/10.3390/jpm12020258 [MDPI]（external link）
  15. Ono T, Yoshimatsu Y, Noguchi R, Sin Y, Tsuchiya R, Akiyama T, Sugaya J, Fukushima S, Kojima N, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-UPS4-C1: a novel cell line of undifferentiated pleomorphic sarcoma from a patient with Li-Fraumeni syndrome. Hum Cell. 2022 Feb 3. doi: 10.1007/s13577-022-00671-y. Epub ahead of print. PMID: 35118583. [PubMed]（external link）
  16. Tsuchiya R, Yoshimatsu Y, Noguchi R, Sin Y, Ono T, Akiyama T, Sugaya J, Kobayashi E, Kojima N, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-MFS5-C1: a novel patient-derived cell line of myxofibrosarcoma. Cells 2022, 11(2), 207; https://doi.org/10.3390/cells11020207 (registering DOI)
  17. Sin Y, Yoshimatsu Y, Noguchi R, Tsuchiya R, Ono T, Akiyama T, Nakatani F, Sugaya J, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-MPNST6-C1: a novel patient-derived cell line of malignant peripheral nerve sheath tumors. Hum Cell. 2022 Jan;35(1):400-407. doi:10.1007/s13577-021-00643-8. Epub 2021 Nov 14. PMID: 34775549. [PubMed]（external link）
  18. Noguchi R, Yoshimatsu Y, Ono T, Sei A, Motoi N, Yatabe Y, Yoshida Y, Watanabe S, Kondo T. Establishment and characterization of NCC-DMM1-C1, a novel patient-derived cell line of desmoplastic malignant pleural mesothelioma. Oncol Lett. 2022 Feb;23(2):64. doi: 10.3892/ol.2021.13182. Epub 2021 Dec 27. PMID: 35069873; PMCID: PMC8756558. [PubMed]（external link）
  19. Ono T, Noguchi R, Yoshimatsu Y, Tsuchiya R, Sin Y, Nakagawa R, Hirabayashi K, Ozawa I, Kikuta K, Kondo T. Establishment and characterization of the NCC-GCTB4-C1 cell line: a novel patient-derived cell line from giant cell tumor of bone. Hum Cell. 2022 Jan;35(1):392-399. doi: 10.1007/s13577-021-00639-4. Epub 2021 Nov 3. PMID: 34731453. [PubMed]（external link）
  20. Tsuchiya R, Yoshimatsu Y, Noguchi R, Sin Y, Ono T, Akiyama T, Sugaya J, Nakatani F, Kojima N, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-UPS3-C1: a novel patient-derived cell line of undifferentiated pleomorphic sarcoma. Hum Cell. 2022 Jan;35(1):384-391. doi:10.1007/s13577-021-00633-w. Epub 2021 Oct 19. PMID: 34665443. [PubMed]（external link）

2021

  1. Tsuchiya R, Yoshimatsu Y, Noguchi R, Sin Y, Ono T, Akiyama T, Hirose T, Iwata S, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-DDLPS4-C1: a novel patient-derived cell line of dedifferentiated liposarcoma.Pers. Med. 2021, 11, 1075. [MDPI]（external link）
  2. Ono T, Noguchi R, Yoshimatsu Y, Sin Yooksil, Kojima N, Kondo T. Development of different organ derived decellularized tissue gels that support in vitro tumor cell behavior in a tumor type-specific manner. J Electrophoresis. 2021 65(1): 33-37. [J-Stage]（external link）
  3. Komatsu A, Matsumoto K, Yoshimatsu Y, Sin Y, Kubota A, Saito T, Muzumoto A, Ohashi S, Muto Manabu, Noguchi R, Kondo T, Tamanoi F. The CAM Model for CIC-DUX4 Sarcoma and Its Potential Use for Precision Medicine. Cells 2021; 10, 2613-24. [PubMed]（external link）
  4. Yoshimatsu Y, Noguchi R, Sin Y, Tsuchiya R, Ono T, Sei A, Sugaya J, Iwata S, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-LGFMS1-C1: a novel patient-derived cell line of low-grade fibromyxoid sarcoma. Hum Cell. 2021 Nov;34(6):1919-1928. doi: 10.1007/s13577-021-00612-1. Epub 2021 Sep 17. PMID: 34535876. [PubMed]（external link）
  5. Yamawaki K, Mori Y, Sakai H, Kanda Y, Shiokawa D, Ueda H, Ishiguro T, Yoshihara K, Nagasaka K, Onda T, Kato T, Kondo T, Enomoto T, Okamoto K. Integrative analyses of gene expression and chemosensitivity of patient-derived ovarian cancer spheroids link G6PD-driven redox metabolism to cisplatin chemoresistance. Cancer Lett. 2021 Aug 19. doi: 10.1016/j.canlet.2021.08.018. Epub ahead of print. PMID: 34419499. [PubMed]（external link）
  6. Yoshimatsu Y, Noguchi R, Tsuchiya R, Sin Y, Ono T, Sugaya J, Iwata S, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-MFS4-C1: a novel patient-derived cell line of myxofibrosarcoma. Hum Cell. 2021 Nov;34(6):1911-1918. doi: 10.1007/s13577-021-00589-x. Epub 2021 Aug 12. PMID: 34383271. [PubMed]（external link）
  7. Yoshimatsu Y, Noguchi R, Tsuchiya R, Ono T, Sin Y, Akane S, Sugaya J, Mori T, Fukushima S, Yoshida A, Kawai A, Kondo T. Establishment and characterization of novel patient-derived cell lines from giant cell tumor of bone. Hum Cell. 2021 Nov;34(6):1899-1910. doi: 10.1007/s13577-021-00579-z. Epub 2021 Jul 24. PMID: 34304386. [PubMed]（external link）
  8. DeSalvo J, Ban Y, Li L, Sun X, Jiang Z, Kerr DA, Khanlari M, Boulina M, Capecchi MR, Partanen JM, Chen L, Kondo T, Ornitz DM, Trent JC, Eid JE. ETV4 and ETV5 drive synovial sarcoma through cell cycle and DUX4 embryonic pathway control. J Clin Invest. 2021 Jul 1;131(13):e141908. doi: 10.1172/JCI141908. PMID: 33983905; PMCID: PMC8245179. [PubMed]（external link）
  9. Takamizawa Y, shida D, Horie T, Tsukamoto S, Esaki M, Shimada K, Kondo T, Kanemitsu Y. Prognostic role for primary tumor location in patients with colorectal liver metastases: A comparison of right-sided colon, left-sided colon, and rectum. Dis Colon rectum. In press. 
  10. Tsuchiya R, Yoshimatsu Y, Noguchi R, Sin Y, Ono T, Sei A, Takeshita F, Sugaya J, Nakatani F, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-ssRMS2-C1: a novel patient-derived cell line of spindle cell/sclerosing rhabdomyosarcoma. Hum Cell. 2021 Sep;34(5):1569-1578. doi: 10.1007/s13577-021-00569-1. Epub 2021 Jun 23. PMID: 34164773. [PubMed]（external link）
  11. Noguchi R, Yoshimatsu Y, Sei A, Yoshida H, Katou T, Kondo T. Drug screening and kinase activity profiling of a novel patient-derived cell line of clear cell ovarian carcinoma. J Electrophoresis. 2021:65:23-31. [J-Stage]（external link）
  12. Tsuchiya R, Yoshimatsu Y, Noguchi R, Sin Y, Ono T, Sei A, Takeshita F, Sugaya J, Iwata S, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-MFS3-C1: a novel patient-derived cell line of myxofibrosarcoma. Hum Cell. 2021 Jul;34(4):1266-1273. doi: 10.1007/s13577-021-00548-6. Epub 2021 May 15. PMID: 33990915. [PubMed]（external link）
  13. Tsuchiya R, Yoshimatsu Y, Noguchi R, Ono T, Sei A, Takeshita F, Sugaya J, Fukushima S, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-DDLPS3-C1: a novel patient-derived cell line of dedifferentiated liposarcoma. Hum Cell. 2021 May;34(3):1008-1018. doi:10.1007/s13577-021-00515-1. Epub 2021 Mar 6. PMID: 33677797. [PubMed]（external link）
  14. Ozawa T, Kaneko S, Szulzewsky F, Qiao Z, Takadera M, Narita Y, Kondo T, Holland EC, Hamamoto R, Ichimura K. C11orf95-RELA fusion drives aberrant gene expression through the unique epigenetic regulation for ependymoma formation. Acta Neuropathol Commun. 2021 Mar 8;9(1):36. doi: 10.1186/s40478-021-01135-4.PMID: 33685520; PMCID: PMC7941712. [PubMed]（external link）
  15. Tsuchiya R, Yoshimatsu Y, Tsuchiya N, Ohtori S, Kawai A, Kondo T. Comprehensive miRNA expression analysis for histological subtypes of soft tissue sarcoma. J Electrophoresis. 2021: 65: 13-22. doi:https://doi.org/10.2198/jelectroph.65.13 [J-Stage]（external link）
  16. Noguchi R, Yoshimatsu Y, Ono T, Sei A, Kondo T. Proteogenomics approach to drug targets in osteosarcomas with different original sites. J Electrophoresis. 2021 65:1-11. doi:https://doi.org/10.2198/jelectroph.65.1 [J-Stage]（external link）
  17. Noguchi R, Yoshimatsu Y, Sei A, Hirabayashi K, Ozawa I, Kikuta K, Kondo T. Establishment and characterization of NCC-MLPS1-C1: a novel patient-derived cell line of myxoid liposarcoma. Hum Cell. 2021 Mar;34(2):667-674. doi: 10.1007/s13577-020-00454-3. Epub 2020 Nov 4. PMID: 33146842. [PubMed]（external link）
  18. Noguchi R, Yoshimatsu Y, Ono T, Sei A, Hirabayashi K, Ozawa I, Kikuta K, Kondo T. Establishment and characterization of NCC-PLPS1-C1, a novel patient-derived cell line of pleomorphic liposarcoma. Hum Cell. 2021 Mar;34(2):688-697. doi: 10.1007/s13577-020-00457-0. Epub 2020 Nov 17. PMID: 33205363. [PubMed]（external link）
  19. Tsuchiya R, Yoshimatsu Y, Noguchi R, Ono T, Sei A, Takeshita F, Sugaya J, Iwata S, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-SS4-C1: a novel patient-derived cell line of synovial sarcoma. Hum Cell. 2021 May;34(3):998-1007. doi: 10.1007/s13577-021-00509-z. Epub 2021 Feb 20. PMID: 33611700. [PubMed]（external link）
  20. Noguchi R, Yoshimatsu Y, Ono T, Sei A, Hirabayashi K, Ozawa I, Kikuta K, Kondo T. Establishment and characterization of a novel cell line, NCC-DDLPS2-C1, derived from a patient with dedifferentiated liposarcoma. Hum Cell. 2021 May;34(3):990-997. doi: 10.1007/s13577-021-00497-0. Epub 2021 Feb 8. PMID: 33555519. [PubMed]（external link）
  21. Hirozane T, Masuda M, Sugano T, Sekita T, Goto N, Aoyama T, Sakagami T, Uno Y, Moriyama H, Sawa M, Asano N, Nakamura M, Matsumoto M, Nakayama R, Kondo T, Kawai A, Kobayashi E, Yamada T. Direct conversion of osteosarcoma to adipocytes by targeting TNIK. JCI Insight. 2021 Feb 8;6(3):137245. doi: 10.1172/jci.insight.137245. PMID: 33400690. [PubMed]（external link）
  22. Hamoya T, Fujii G, Iizumi Y, Narita T, Komiya M, Matsuzawa Y, Miki K, Kondo T, Kishimoto S, Watanabe K, Wakabayashi K, Sakai T, Toshima J, Mutoh M. Artesunate inhibits intestinal tumorigenesis through inhibiting wnt signaling. Carcinogenesis. 2021 Feb 11;42(1):148-158. doi:10.1093/carcin/bgaa084. PMID: 32710739. [PubMed]（external link）
  23. Jimura N, Fujii K, Qiao Z, Tsuchiya R, Yoshimatsu Y, Kondo T, Kanekura T. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma. J Dermatol Sci. 2021 Mar;101(3):194-201. doi: 10.1016/j.jdermsci.2021.01.004. Epub 2021 Jan 22. PMID: 33531202. [PubMed]（external link）
  24. Nakano Y, Takadera M, Miyazaki M, Qiao Z, Nakajima K, Noguchi R, Oyama R, Kimura Y, Okuhiro Y, Yamasaki K, Kunihiro N, Fukushima H, Inoue T, Hara J, Ozawa T, Kondo T, Ichimura K. Drug screening with a novel tumor-derived cell line identified alternative therapeutic options for patients with atypical teratoid/rhabdoid tumor. Hum Cell. 2021 Jan;34(1):271-278. doi: 10.1007/s13577-020-00438-3. Epub 2020 Sep 30. PMID: 32997328. [PubMed]（external link）
  25. Noguchi R, Yoshimatsu Y, Ono T, Sei A, Hirabayashi K, Ozawa I, Kikuta K, Kondo T. Establishment and characterization of NCC-MFS2-C1: a novel patient-derived cancer cell line of myxofibrosarcoma. Hum Cell. 2021 Jan;34(1):246-253. doi: 10.1007/s13577-020-00420-z. Epub 2020 Sep 1. PMID: 32870449. [PubMed]（external link）
  26. Noguchi R, Yoshimatsu Y, Ono T, Sei A, Hirabayashi K, Ozawa I, Kikuta K, Kondo T. Establishment and characterization of a novel cell line, NCC-TGCT1-C1, derived from a patient with tenosynovial giant cell tumor. Hum Cell. 2021 Jan;34(1):254-259. doi: 10.1007/s13577-020-00425-8. Epub 2020 Sep 4. PMID:32886306. [PubMed]（external link）
  27. Tsuchiya R, Yoshimatsu Y, Noguchi R, Sei A, Takeshita F, Sugaya J, Fukushima S, Yoshida A, Ohtori S, Kawai A, Kondo T. Establishment and characterization of NCC-DDLPS1-C1: a novel patient-derived cell line of dedifferentiated liposarcoma. Hum Cell. 2021 Jan;34(1):260-270. doi: 10.1007/s13577-020-00436-5. Epub 2020 Sep 19. PMID: 32949334. [PubMed]（external link）
  28. Noguchi R, Yoshimatsu Y, Ono T, Sei A, Hirabayashi K, Ozawa I, Kikuta K, Kondo T. Establishment and characterization of NCC-LMS2-C1-a novel patient- derived cancer cell line of leiomyosarcoma. Hum Cell. 2021 Jan;34(1):279-288. doi: 10.1007/s13577-020-00443-6. Epub 2020 Oct 1. PMID: 33001379.[PubMed]（external link）
  29. Kondo T. Current status and future outlook for patient-derived cancer models from a rare cancer research perspective. Cancer Sci. 2021 Mar;112(3):953-961. doi: 10.1111/cas.14669. Epub 2021 Feb 6. PMID: 32986888; PMCID: PMC7935796. [PubMed]（external link）

2020

  1. Noguchi R, Yoshimatsu Y, Ono T, Sei A, Hirabayashi K, Ozawa I, Kikuta K, Kondo T. Establishment and characterization of NCC-GCTB1-C1: a novel patient-derived cancer cell line of giant cell tumor of bone. Hum Cell. 2020 Oct;33(4):1321-1328. doi: 10.1007/s13577-020-00415-w. Epub 2020 Aug 19. PMID:32815117. [PubMed]（external link）
  2. Sin Y, Yoshimatsu Y, Noguchi R, Tsuchiya R, Sei A, Ono T, Toki S, Kobayashi E, Arakawa A, Sugiyama M, Yoshida A, Kawai A, Kondo T. Establishment and characterization of a novel alveolar rhabdomyosarcoma cell line, NCC-aRMS1-C1. Hum Cell. 2020 Oct;33(4):1311-1320. doi: 10.1007/s13577-020-00403-0. Epub 2020 Jul 26. PMID: 32715445. [PubMed]（external link）
  3. Yoshimatsu Y, Noguchi R, Tsuchiya R, Sei A, Sugaya J, Fukushima S, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-ASPS1-C1: a novel patient-derived cell line of alveolar soft-part sarcoma. Hum Cell. 2020 Oct;33(4):1302-1310. doi: 10.1007/s13577-020-00382-2. Epub 2020 Jul 10. PMID:32648033. [PubMed]（external link）
  4. Yoshimatsu Y, Noguchi R, Tsuchiya R, Sei A, Nakagawa M, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-DFSP3-C1: a novel patient-derived dermatofibrosarcoma protuberans cell line. Hum Cell. 2020 Jul;33(3):894-903. doi: 10.1007/s13577-020-00365-3. Epub 2020 Apr 30. PMID: 32356243. [PubMed]（external link）
  5. Yoshimatsu Y, Noguchi R, Tsuchiya R, Sei A, Sugaya J, Iwata S, Sugiyama M, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-ssRMS1-C1: a novel patient-derived spindle-cell/sclerosing rhabdomyosarcoma cell line. Hum Cell. 2020 Jul;33(3):886-893. doi: 10.1007/s13577-020-00359-1. Epub 2020 Apr 16. PMID: 32300959. [PubMed]（external link）
  6. Yoshimatsu Y, Noguchi R, Tsuchiya R, Sei A, Sugaya J, Iwata S, Yoshida A, Kawai A, Kondo T. Establishment and characterization of NCC-SS3-C1: a novel patient-derived cell line of synovial sarcoma. Hum Cell. 2020 Jul;33(3):877-885. doi: 10.1007/s13577-020-00354-6. Epub 2020 Apr 9. PMID: 32274656. [PubMed]（external link）
  7. Yoshimatsu Y, Noguchi R, Tsuchiya R, Kito F, Sei A, Sugaya J, Nakagawa M, Yoshida A, Iwata S, Kawai A, Kondo T. Establishment and characterization of NCC-CDS2-C1: a novel patient-derived cell line of CIC-DUX4 sarcoma. Hum Cell. 2020 Apr;33(2):427-436. doi: 10.1007/s13577-019-00312-x. Epub 2020 Jan 2. PMID:31898195. [PubMed]（external link）
  8. Yasukawa M, Ando Y, Yamashita T, Matsuda Y, Shoji S, Morioka MS, Kawaji H, Shiozawa K, Machitani M, Abe T, Yamada S, Kaneko MK, Kato Y, Furuta Y, Kondo T, Shirouzu M, Hayashizaki Y, Kaneko S, Masutomi K. CDK1 dependent phosphorylation of hTERT contributes to cancer progression. Nat Commun. 2020 Mar 25;11(1):1557. doi: 10.1038/s41467-020-15289-7. PubMed PMID: 32214089; PubMed Central PMCID: PMC7096428. [PubMed]（external link）
  9. Oyama R, Kito F, Takahashi M, Hattori E, Noguchi R, Takai Y, Sakumoto M, Qiao Z, Toki S, Sugawara M, Tanzawa Y, Kobayashi E, Nakatani F, Iwata S, Yoshida A, Kawai A, Kondo T. Establishment and characterization of patient-derived cancer models of malignant peripheral nerve sheath tumors. Cancer Cell Int. 2020 Feb 19. doi: 10.1186/s12935-020-1128-z. PMID: 32099531; PMCID: PMC7031935. [PubMed]（external link）
  10. Kito F, Oyama R, Noguchi R, Hattori E, Sakumoto M, Endo M, Kobayashi E, Yoshida A, Kawai A, Kondo T. Establishment and characterization of novel patient-derived extraskeletal osteosarcoma cell line NCC-ESOS1-C1. Hum Cell. 2020 Jan;33(1):283-290. doi: 10.1007/s13577-019-00291-z. Epub 2019 Oct 17. PMID:31625124. [PubMed]（external link）
  11. Noguchi R, Sin Y, Kondo T. Gel electrophoresis for phosphorylated proteins: a brief introduction. J Electrophoresis. J Electrophoresis. 2020 64(1):13-17［PubMed］(external link)
  12. Kondo T. Current status and future outlook for patient-derived cancer models from a rare cancer research perspective. Cancer Sci. 2020 Sep 28. doi: 10.1111/cas.14669. Epub ahead of print. PMID: 32986888. [PubMed]（external link）
  13. Kondo T. Current status and perspectives of patient-derived rare cancer models. Hum Cell. 2020 Oct;33(4):919-929. doi: 10.1007/s13577-020-00391-1. Epub 2020 Jun 14. PMID: 32537685. [PubMed]（external link）
  14. Kondo T. Necessity of guidelines for publication of patient-derived cancer models. Ann Transl Med. 2020 Mar;8(5):158. doi: 10.21037/atm.2019.12.144. PMID:32309306; PMCID: PMC7154464. [PubMed]（external link）

2019

  1. Asano N, Takeshima H, Yamashita S, Takamatsu H, Hattori N, Kubo T, Yoshida A, Kobayashi E, Nakayama R, Matsumoto M, Nakamura M, Ichikawa H, Kawai A, Kondo T, Ushijima T. Epigenetic reprogramming underlies efficacy of DNA demethylation therapy in osteosarcomas. Sci Rep. 2019 Dec 30;9(1):20360. doi:10.1038/s41598-019-56883-0. PubMed PMID: 31889115.
  2. Hirata M, Asano N, Katayama K, Yoshida A, Tsuda Y, Sekimizu M, Mitani S, Kobayashi E, Komiyama M, Fujimoto H, Goto T, Iwamoto Y, Naka N, Iwata S, Nishida Y, Hiruma T, Hiraga H, Kawano H, Motoi T, Oda Y, Matsubara D, Fujita M, Shibata T, Nakagawa H, Nakayama R, Kondo T, Imoto S, Miyano S, Kawai A, Yamaguchi R, Ichikawa H, Matsuda K. Integrated exome and RNA sequencing of dedifferentiated liposarcoma. Nat Commun. 2019 Dec 12;10(1):5683 . doi: 10.1038/s41467-019-13286-z. PubMed PMID: 31831742.
  3. Kito F, Oyama R, Noguchi R, Hattori E, Sakumoto M, Endo M, Kobayashi E, Yoshida A, Kawai A, Kondo T. Establishment and characterization of novel patient-derived extraskeletal osteosarcoma cell line NCC-ESOS1-C1. Hum Cell. 2019 Oct 17. doi: 10.1007/s13577-019-00291-z. [Epub ahead of print] PubMed PMID: 31625124.
  4. Shiozawa K, Oyama R, Takahashi M, Kito F, Hattori E, Yoshida A, Kawai A, Ono M, Kondo T. Species-Specific Quantitative Proteomics Profiles of Sarcoma Patient-Derived Models Closely Reflect Their Primary Tumors. Proteomics Clin Appl. 2019 Aug 16:e1900054. doi: 10.1002/prca.201900054. [Epub ahead of print] PubMed PMID: 31419061.
  5. Okimoto RA, Wu W, Nanjo S, Olivas V, Lin YK, Ponce RK, Oyama R, Kondo T, Bivona TG. CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs. J Clin Invest. 2019 Jul 22;129(8):3401-3406. doi:10.1172/JCI126366. eCollection 2019 Jul 22. PubMed PMID: 31329165; PubMed Central PMCID: PMC6668665.
  6. Jia X, Chen C, Chen L, Yu C, Kondo T. Decorin as a prognostic biomarker in patients with malignant peripheral nerve sheath tumors. Oncol Lett. 2019 Mar;17(3):3517-3522. doi: 10.3892/ol.2019.9959. Epub 2019 Jan 23. PubMed PMID: 30867792; PubMed Central PMCID: PMC6396138.
  7. Tajima T, Kito F, Yoshida A, Kawai A, Kondo T. Calreticulin as A Novel Potential Metastasis-Associated Protein in Myxoid Liposarcoma, as Revealed by Two-Dimensional Difference Gel Electrophoresis. Proteomes. 2019 Apr 10;7(2). pii: E13. doi: 10.3390/proteomes7020013. PubMed PMID: 30974841.
  8. Asano N, Matsuzaki J, Ichikawa M, Kawauchi J, Takizawa S, Aoki Y, Sakamoto H, Yoshida A, Kobayashi E, Tanzawa Y, Nakayama R, Morioka H, Matsumoto M, Nakamura　M, Kondo T, Kato K, Tsuchiya N, Kawai A, Ochiya T. A serum microRNA classifier　for the diagnosis of sarcomas of various histological subtypes. Nat Commun. 2019 Mar 21;10(1):1299. doi: 10.1038/s41467-019-09143-8. PubMed PMID: 30898996
  9. Kito F, Oyama R, Sakumoto M, Shiozawa K, Qiao Z, Toki S, Yoshida A, Kawai A, Kondo T. Establishment and characterization of a novel cell line, NCC-MFS1-C1, derived from a patient with myxofibrosarcoma. Hum Cell. 2019 Apr;32(2):214-222. doi: 10.1007/s13577-018-00233-1. PubMed PMID: 30737712.head of print] PubMed PMID: 30737712
  10. Oyama R, Kito F, Takahashi M, Sakumoto M, Shiozawa K, Qiao Z, Noguchi R, Kubo T, Toki S, Nakatani F, Yoshida A, Kawai A, Kondo T. Establishment and characterization of a novel dedifferentiated chondrosarcoma cell line, NCC-dCS1-C1. Hum Cell. 2019 Apr;32(2):202-213. doi: 10.1007/s13577-018-00232-2. PubMed PMID: 30737713.
  11. Oyama R, Takahashi M, Kito F, Sakumoto M, Takai Y, Kumiko S, Qiao Z, Toki S, Tanzawa Y, Yoshida A, Kawai A, Kondo T. Establishment and characterization of patient-derived pleomorphic rhabdomyosarcoma models. Tiss. Cult. Res. Commun. 2019;38(1)1-12. [J-Stage（PDF:1151KB）](external link)
  12. Qiao Z, Kondo T. Screening of a growth inhibitor library of sarcoma cell lines to identify potent anti-cancer drugs.J Electrophoresis. 2019 63:1-7. [J Electrophoresis](external link)
  13. Qiao Z, Kondo T. Identification of cantharidin as a drug candidate for glioblastoma by using a Connectivity Map-based approach. J Electrophoresis. 2019 63:9-14. [J Electrophoresis](external link)
  14. Patel N, Wang J, Shiozawa K, Jones KB, Zhang Y, Prokop JW, Davenport GG, Nihira NT, Hao Z, Wong D, Brandsmeier L, Meadows SK, Sampaio AV, Werff RV, Endo M, Capecchi MR, McNagny KM, Mak TW, Nielsen TO, Underhill TM, Myers RM, Kondo T, Su L. HDAC2 regulates site-specific acetylation of MDM2 and its ubiquitination signaling in tumor suppression. iSci. 2019 Feb 15. doi:10.1016/j.isci.2019.02.0082. [iScience](external link)
  15. Oyama R, Kito F, Qiao Z, Sakumoto M, Shiozawa K, Toki S, Yoshida A, Kawai A, Kondo T. Establishment of novel patient-derived models of dermatofibrosarcoma protuberans: two cell lines, NCC-DFSP1-C1 and NCC-DFSP2-C1. In Vitro Cell Dev Biol Anim. 2019 Jan;55(1):62-73. doi: 10.1007/s11626-018-0305-z. PubMed PMID: 30411273.
  16. Hattori E, Kondo T. Current status of cancer proteogenomics: a brief introduction. J Electrophoresis. 2019 63:33-37 [J-Stage]（external link）
  17. Kondo T. Cancer biomarker development and two-dimensional difference gel electrophoresis (2D-DIGE). Biochim Biophys Acta Proteins Proteom. 2019 Jan;1867(1):2-8. doi: 10.1016/j.bbapap.2018.07.002. Epub 2018 Jul 7. Review. PubMed PMID: 30392560. ［PubMed］(external link)

2018

  1. Qiao Z, Parlayan C, Saito S, Kondo T. Meta-analysis of global gene-expression profiles identify molecular signatures for histological subtypes of sarcomas. J Electrophoresis. 2018 62:21-29. [J Electrophoresis](external link)
  2. Shiozawa K, Yoshioka Y, Qiao Z, Shuting J, Ochiya T, Kondo T.　Pazopanib-induced changes in protein expression signatures of extracellular vesicles in synovial sarcoma. Biochem Biophys Res Commun. 2018 Nov 30;506(3):723-730. doi: 10.1016/j.bbrc.2018.10.012. Epub 2018 Oct 27. PubMed PMID: 30454707.
  3. Oyama R, Kito F, Qiao Z, Sakumoto M, Noguchi R, Takahashi M, Toki S, Tanzawa Y, Yoshida A, Kawai A, Kondo T. Establishment of a novel patient-derived Ewing's sarcoma cell line, NCC-ES1-C1. In Vitro Cell Dev Biol Anim. 2018 Dec;54(10):770-778. doi: 10.1007/s11626-018-0302-2. Epub 2018 Oct 15. PubMed PMID: 30324244.
  4. Qiao Z, Kondo T. Identification of cephalomannine as a drug candidate for glioblastoma via high-throughput drug screening. J Electrophoresis 2018;62:17 doi:10.2198/jelectroph. 62.17
  5. Kito F, Oyama R, Sakumoto M, Takahashi M, Shiozawa K, Qiao Z, Sakamoto H, Hirose T, Setsu N, Yoshida A, Kawai A, Kondo T. Establishment and characterization of novel patient-derived osteosarcoma xenograft and cell line. In Vitro Cell Dev Biol Anim. 2018 Jun 25. doi: 10.1007/s11626-018-0274-2. PubMed PMID: 29943355.
  6. Kito F, Oyama R, Takahashi M, Shiozawa K, Sakumoto M, Yoshida A, Setsu N, Kobayashi E, Kawai A, Kondo T. Establishment and characterization of a patient-derived cancer model of undifferentiated pleomorphic sarcoma. Tiss. Cult. Res. Commun. 37: 1–13 (2018)[J-Stage](external link)
  7. Oyama R, Takahashi M, Kito F, Sakumoto M, Shiozawa K, Qiao Z, Yoshida A, Endo M, Kawai A, Kondo T. Establishment and characterization of patient-derived xenograft and its cell line of primary leiomyosarcoma of bone. In Vitro Cell Dev Biol Anim. 2018 Jun;54(6):458-467. doi: 10.1007/s11626-018-0258-2. Epub 2018 May 29.  [PubMed](external link)
  8. Kito F, Oyama R, Takai Y, Sakumoto M, Shiozawa K, Qiao Z, Uehara T, Yoshida A, Kawai A, Kondo T. Establishment and characterization of the NCC-SS1-C1 synovial sarcoma cell line. Hum Cell. 2018 Apr;31(2):167-174. doi: 10.1007/s13577-018-0199-9. Epub 2018 Feb 15.  [PubMed](external link)
  9. Oyama R, Kito F, Sakumoto M, Shiozawa K, Toki S, Endo M, Yoshida A, Kawai A, Kondo T. Establishment and proteomic characterization of a novel synovial sarcoma cell line, NCC-SS2-C1. In Vitro Cell Dev Biol Anim. 2018 May;54(5):392-399. doi:  10.1007/s11626-018-0237-7. Epub 2018 Apr 6.  [PubMed](external link)
  10. Fujii K, Suzuki N, Jimura N, Idogawa M, Kondo T, Iwatsuki K, Kanekura T. HSP72 functionally inhibits the anti-neoplastic effects of HDAC inhibitors. J Dermatol Sci. 2018 Jan 30. pii: S0923-1811(18)30018-5. doi:10.1016/j.jdermsci.2018.01.002. [Epub ahead of print] [PubMed](external link)
  11. Oyama R, Kito F, Sakumoto M, Shiozawa K, Toki S, Yoshida A, Kawai A, Kondo T. Establishment and proteomic characterization of a novel cell line, NCC-UPS2-C1, derived from a patient with undifferentiated pleomorphic sarcoma. In Vitro Cell Dev Biol Anim. 2018 Mar;54(3):257-263. doi: 10.1007/s11626-018-0229-7. Epub 2018 Jan 22. [PubMed](external link)
  12. Sakumoto M, Oyama R, Takahashi M, Takai Y, Kito F, Shiozawa K, Qiao Z, Endo M, Yoshida A, Kawai A, Kondo T. Establishment and proteomic characterization of patient-derived clear cell sarcoma xenografts and cell lines. In Vitro Cell Dev Biol Anim. 2018 Feb;54(2):163-176. [PubMed](external link)
  13. Shiozawa K, Shuting J, Yoshioka Y, Ochiya T, Kondo T. Extracellular vesicle-encapsulated microRNA-761 enhances pazopanib resistance in synovial sarcoma. Biochem Biophys Res Commun. 2018 Jan 1;495(1):1322-1327. [PubMed](external link)
  14. Kondo T. Mass Spectrometry and Proteomics 2018: the Mass Spectrometry Society of Japan, Japanese Proteomics Society, and Asia-Oceania Human Proteome Organization. Expert Rev Proteomics. 2018 Oct;15(10):777-779. doi:10.1080/14789450.2018.1525297. Epub 2018 Sep 21. PMID: 30223682. [PubMed]（external link）
  15. Kondo T. Current Status of Proteomics in Ewing's Sarcoma. Proteomics Clin Appl. 2019 May;13(3):e1700130. doi: 10.1002/prca.201700130. Epub 2018 Aug 23. Review. PubMed PMID: 29992772. [PubMed]（external link） 

2017

  1. Takai Y, Oyama R, Kito F, Sakumoto M, Shiozawa K, Qiao Z, Nakajima K, Takahashi M, Yoshida A, Setsu N, Kobayashi E, Kawai A, Kondo T. Establishment and characterization of cell line of undifferentiated pleomorphic sarcoma. Tiss Cult Res Comm.2017;36(5)41-48. [J-Stage（PDF:493KB）](external link)
  2. Qiao Z, Shiozawa K, Kondo T. Proteomic approach toward determining the molecular background of pazopanib resistance in synovial sarcoma. Oncotarget. 2017 Nov 28;8(65):109587-109595. [PubMed](external link)
  3. Qiao Z, Kito F, Kondo T. Meta-analysis identifies endothelin-3 as a prognostic biomarker in gastrointestinal stromal tumors. J Sarcoma Res [J Sarcoma Res（PDF:2.7MB）](external link)
  4. Qiao Z, Tajim T, Kito F, Arai Y, Kawai A, Kondo T. Metastasis-associated gene signature in primary myxoid liposarcoma identified through a gene expression study. J Electrophoresis. 2017 61(1):9-15.[J Electrophoresis](external link)
  5. Qiao Z, Kito F, Takai Y, Oyama R, Kondo T. Secretomics identifies follistatin as a predictive biomarker for response to treatment with tyrosine kinase inhibitors in synovial sarcoma. J Electrophoresis. 2017 61(1):1-7.[J Electrophoresis](external link)
  6. Sakumoto M, Takahashi M, Oyama R, Takai Y, Kito F, Shiozawa K, Qiao Z, Yoshida A, Endo M, Kawai A, Kondo T. Establishment and proteomic characterization of NCC-LMS1-C1, a novel cell line of primary leiomyosarcoma in the bone. Jap J Clin Oncol. 2017 Oct 1;47(10):954-961.[PubMed](external link)
  7. Kikuta K, Kubata D, Yoshida A, Qiao Z, Morioka H, Nakamura M, Matsumoto M, Chuman H, Kawai A. Discoidin, CUB and LCCL domain-containing protein 2 (DCBLD2) is a novel biomarker of myxofibrosarcoma invasion identified by global protein expression profiling. Biochim Biophys Acta. 2017 Jun 29;1865(9):1160-1166.[PubMed](external link)
  8. Oyama R, Takahashi M, Yoshida A, Sakumoto M, Takai Y, Kito F, Shiozawa K, Qiao Z, Arai Y, Shibata T, Araki Y, Endo M, Kawai A, Kondo T. Generation of novel patient-derived CIC-DUX4 sarcoma xenografts and cell lines. Sci Rep.2017 Jul 5;7(1):4712.[PubMed](external link)
  9. Nakasuji T, Ogonuki N, Chiba T, Kato T, Shiozawa K, Yamatoya K, Tanaka H, Kondo T, Miyado K, Miyasaka N, Kubota T, Ogura A, Asahara H. Complementary Critical Functions of Zfy1 and Zfy2 in Mouse Spermatogenesis and Reproduction. PLoS Genet. 2017 Jan 23;13(1):e1006578. doi: 10.1371/journal.pgen.1006578. eCollection 2017 Jan.[PubMed](external link)
  10. Asano N, Yoshida A, Mitani S, Kobayashi E, Shiotani B, Komiyama M, Fujimoto H, Chuman H, Morioka H, Matsumoto M, Nakamura M, Kubo T, Kato M, Kohno T, Kawai A, Kondo T, Ichikawa H. Frequent amplification of receptor tyrosine kinase genes in welldifferentiated/ dedifferentiated liposarcoma. Oncotarget. 2017 Feb 21;8(8):12941-12952. doi: 10.18632/oncotarget.14652.[PubMed](external link)
  11. Kondo T. Current status of proteomics of soft tissue sarcomas. Expert Rev Proteomics. 2017 Dec;14(12):1131-1140. doi: 10.1080/14789450.2017.1394190. Epub 2017 Oct 25. Review. PMID: 29039718. [PubMed]（external link）
  12. Kondo T. Omics approach for identifying predictive biomarkers in osteosarcoma. Osteosarcoma – Biology, Behavior and Mechanisms. InTech, 2017, DOI:10.5772/67449  [ResearchGate]（external link）

2016

  1. Kubota D, Kosaka N, Fujiwara T, Yoshida A, Arai Y, Qiao Z, Takeshita F, Ochiya T, Kawai A, Kondo T. miR-125b and miR-100 Are Predictive Biomarkers of Response to Induction Chemotherapy in Osteosarcoma. Sarcoma. 2016;2016時13分90571.[PubMed](external link)
  2. Yamasaki H, Miyamoto M, Yamamoto Y, Kondo T, Watanabe T, Ohta T. Synovial sarcoma cell lines showed reduced DNA repair activity and sensitivity to a PARP inhibitor. Genes Cells. 2016 Aug;21(8):852-60. doi: 10.1111/gtc.12387.[PubMed](external link)
  3. Qiao Z, Pan X, Parlayan C, Ojima H, Kondo T. Proteomic study of hepatocellular carcinoma using a novel modified aptamer-based array (SOMAscan™) platform. Biochim Biophys Acta. 2017 Apr;1865(4):434-443. doi:10.1016/j.bbapap.2016.09.011. Epub 2016 Sep 20. PubMed PMID: 27663888.[PubMed](external link)
  4. Jia X, Yang J, Chen L, Yu C, Kondo T. Primary Brachial Plexus Tumors: Clinical Experiences of 143 Cases. Clin Neurol Neurosurg. 2016 Sep;148:91-5. doi: 10.1016/j.clineuro.2016.07.009. Epub 2016 Jul 4. PMID: 27428490. [PubMed](external link)
  5. Ezawa I, Sawai Y, Kawase T, Okabe A, Tsutsumi S, Ichikawa H, Kobayashi Y,　Tashiro F, Namiki H, Kondo T, Semba K, Aburatani H, Taya Y, Nakagama H, Ohki R.　Novel p53 target gene FUCA1 encodes a fucosidase and regulates growth and survival of cancer cells. Cancer Sci. 2016 Jun;107(6):734-45. doi:10.1111/cas.12933. Epub 2016 May 16.[PubMed](external link)
  6. Morofuji N, Ojima H, Hiraoka N, Okusaka T, Esaki M, Nara S, Shimada K, Kishi Y, Kondo T. Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma. Clin Proteomics. 2016 Oct 24;13時28分. eCollection 2016.[PubMed](external link)
  7. Asano Y, Kawase T, Okabe A, Tsutsumi S, Ichikawa H, Tatebe S, Kitabayashi I, Tashiro F, Namiki H, Kondo T, Semba K, Aburatani H, Taya Y, Nakagama H, Ohki R. IER5 generates a novel hypo-phosphorylated active form of HSF1 and contributes to tumorigenesis. Sci Rep. 2016 Jan 12;6時19分174. doi: 10.1038/srep19174.[PubMed](external link)
  8. Takai Y, Matsuo A, Qiao Z, Kondo T. Antitumor activities of BIBF 1120, BI860585, and BI 836845 un preclinical models of sarcoma. Integr Mol Med. 2016 3(4): 755-760, 2016
  9. Pan X, Yoshida A, Kawai A, Kondo T. Current status of publicly available sarcoma cell lines for use in proteomic studies. Expert Rev Proteomics. 2016;13(2):227-40. doi: 10.1586/14789450.2016.1132166. Epub 2016 Jan 11. Review. PMID: 26653594. [PubMed]（external link）
  10. Uemura N, Kondo T. Current status of proteomics of esophageal carcinoma. Expert Rev Proteomics. 2016 Nov;13(11):1029-1040. doi: 10.1080/14789450.2016.1242418. Epub 2016 Oct 8. PubMed PMID: 27678273. [PubMed]（external link）
  11. Kondo T. Proteogenomics for the Study of Gastrointestinal Stromal Tumors. Adv Exp Med Biol. 2016;926:139-151. PubMed PMID: 27686810. [PubMed]（external link）

2015

  1. Tajima T, Kito F, Ohta T, Kawai A, Kondo T. Interactome approach to SBP-1 binding protein in lung adenocarcinoma. J Electrophoresis, 59:1-6, 2015.[J Electrophoresis（PDF:879KB）](external link)
  2. Ichikawa H, Yoshida A, Kanda T, Kosugi S, Ishikawa T, Hanyu T, Taguchi T, Sakumoto M, Katai H, Kawai A, Wakai T, Kondo T. Prognostic significance of promyelocytic leukemia expression in gastrointestinal stromal tumor; integrated proteomic and transcriptomic analysis. Cancer Sci. 2015 Jan;106(1):115-24. doi: 10.1111/cas.12565. Epub 2014 Dec 4.[PubMed](external link)
  3. Kikuta K, Morioka H, Kawai A, Kondo T. Global protein-expression profiling for reclassification of malignant fibrous histiocytoma. Biochim Biophys Acta. 2015 Jun;1854(6):696-701. doi: 10.1016/j.bbapap.2014.08.012. Epub 2014 Aug 28.Review. PMID: 25173742. [PubMed]（external link）
  4. Uemura N, Kondo T. Current advances in esophageal cancer proteomics. Biochim Biophys Acta. 2015 Jun;1854(6):687-95. doi: 10.1016/j.bbapap.2014.09.011. Epub 2014 Sep 16.Review. PMID: 25233958. [PubMed]（external link）
  5. Kondo T. Novel prognostic biomarker, pfetin, in gastrointestinal stromal tumors: proteomics study. General Methods in Biomarker Research and Their Applications. Vol. 1, pp251-266, Series Editor: Victor R. Preedy, Springer, ISBN 2015;978-94-007-7695-1 [ResearchGate]（external link）

2014

  1. Taoka M, Morofuji N, Yamauchi Y, Ojima H, Kubota D, Terukina G, Nobe Y, Nakayama H, Takahashi N, Kosuge T, Isobe T, Kondo T. Global PROTOMAP profiling to search for biomarkers of early-recurrent hepatocellular carcinoma. J Proteome Res. 2014 Jun 26. [Epub ahead of print] PMID: 24967658.[PubMed](external link)
  2. Hosoya N, Sakumoto M, TomitaY, Kondo T. Approach to spot overlapping problem in　2D-PAGE revealed clinical and functional significance of RKIP and MnSOD in renal cell carcinoma. EuPA Open Proteomics 2014 4: 129-139.[EuPaA Open Protreomics](external link)
  3. MukaiharaK, Kubota D, Yoshida A, Kawai A, Kondo T. Proteomic profile of epitheliod sarcoma. J Proteomics Bioinform 2014, 7時7分 158-165.[Proteomics & Bioinformatics（PDF:3.7MB）](external link)
  4. Ito M, Hagiyama M, Mimae T, Inoue T, Kato T, Yoneshige A, Nakanishi J, Kondo T, Okada M, Ito A. α-Parvin, a pseudopodial constituent, promotes cell motility and is associated with lymph node metastasis of lobular breast carcinoma. Breast Cancer Res Treat. 2014 Feb;144(1):59-69. doi: 10.1007/s10549-014-2859-0. Epub 2014 Feb 5.[PubMed](external link)
  5. Fujiwara T, Katsuda T, Hagiwara K, Kosaka N, Yoshioka Y, Takahashi RU, Takeshita F, Kubota D, Kondo T, Ichikawa H, Yoshida A, Kobayashi E, Kawai A, Ozaki T, Ochiya T. Clinical relevance and therapeutic significance of microRNA-133a expression profiles and functions in malignant osteosarcoma-initiating cells. Stem Cells. 2014 Apr;32(4):959-73. doi: 10.1002/stem.1618.[PubMed](external link)
  6. Kubota D, Yoshida A, Kawai A, Kondo T. Proteomics identified overexpression of SET oncogene product and possible therapeutic utility of protein phosphatase 2A in alveolar soft part sarcoma. J Proteome Res. 2014 May 2;13(5):2250-61. doi: 10.1021/pr400929h. Epub 2014 Mar 31.[PubMed](external link)
  7. Mimae T, Ito A, Hagiyama M, Nakanishi J, Hosokawa Y, Okada M, Murakami Y, Kondo T. A novel approach to pseudopodia proteomics: excimer laser etching, two-dimensional difference gel electrophoresis, and confocal imaging. Protoc exch. 2014 Mar 4;2014. pii: 2014.007.[PubMed](external link)
  8. Kubota D, Yoshida A, Kikuta K, Saito T, Suehara Y, Gotoh M, Kawai A, Kondo T. Proteomic approach to gastrointestinal stromal tumor identified prognostic biomarkers. J Proteomics Bioinform 2014, 7時1分 10-16.[Proteomics & Bioinformatics（PDF:972KB）](external link)
  9. Ichikawa H, Kanda T, Kosugi S, Kawachi Y, Wakai T, Kondo T. Proteomic and meta-transcriptomic study on lymph node metastasis in gastric cancer. EuPA Open proteomics. 2014; 3時18分3-194.[EuPaA Open Protreomics](external link)
  10. Kondo T, Kawai A. A Proteomic approach for the development of sarcoma biomarkers. EuPA Open Proteomics 2014;4時12分1-8. [ScienceDirect]（external link）
  11. Uemura N, Kondo T. Current status of predictive biomarkers for neoadjuvant therapy in esophageal cancer. World J Gastrointest Pathophysiol. 2014 Aug 15;5(3):322-34. doi: 10.4291/wjgp.v5.i3.322. Review. PMID: 25133032; PMCID: PMC4133529. [PubMed]（external link）
  12. Kondo T. Inconvenient truth: cancer biomarker development by using proteomics. Biochim Biophys Acta. 2014 May;1844(5):861-5. doi: 10.1016/j.bbapap.2013.07.009. Epub 2013 Jul 27. Review. PMID: 23896458. [PubMed]（external link）
  13. Kondo T. Casting doubt on the traditional approach of cancer biomarker discovery through proteomics. Expert Rev Proteomics. 2014 Feb;11(1):9-12. doi: 10.1586/14789450.2014.871496. Epub 2013 Dec 18.Review. PMID: 24351084. [PubMed]（external link）

2013

  1. Hosoya N, Sakumoto M, Nakamura Y, Narisawa T, Bilim V, Motoyama T, Tomita Y, Kondo T. Proteomics identified nuclear N-myc downstream-regulated gene 1 as a prognostic tissue biomarker candidate in renal cell carcinoma. Biochim Biophys Acta. 2013;1834(12):2630-9. Epub 2013/ 09/ 04. PMID: 23999030.[PubMed](external link)
  2. Kubota D, Yoshida A, Tsuda H, Suehara Y, Okubo T, Saito T, Orita H, Sato K, Taguchi T, Yao T, Kaneko K, Katai H, Kawai A, Kondo T. Gene expression network analysis of ETV1 reveals KCTD10 as a novel prognostic biomarker in gastrointestinal stromal tumor. PloS One. 2013;8(8):e73896. Epub 2013/ 08/ 27. PMID: 23977394.[PubMed](external link)
  3. Kubota D, Mukaihara K, Yoshida A, Tsuda H, Kawai A, Kondo T. Proteomics study of open biopsy samples identifies peroxiredoxin 2 as a predictive biomarker of response to induction chemotherapy in osteosarcoma. J Proteomics. 2013;91C:393-404. Epub 2013/ 08/ 06. PMID: 23911960.[PubMed](external link)
  4. Ichikawa H, Kanda T, Kosugi S. I, Kawachi Y, Sasaki H, Wakai T, Kondo T. Laser microdissection and two-dimensional difference gel electrophoresis reveal the role of a novel macrophage-capping protein in lymph node metastasis in gastric cancer.J Proteome Res. 2013;12(8):3780-91. Epub 2013/ 06/ 21. PMID: 23782053.[PubMed](external link)
  5. Yonemori H, Kubota D, Taniguchi H, Tsuda H, Fujita S, Murakami Y, Kondo T. Laser microdissection and two-dimensional difference gel electrophoresis with alkaline isoelectric point immobiline gel reveals proteomic intra-tumor heterogeneity in colorectal cancer. EuPA Open Proteomics. 2013;1時17分-29.[ScienceDirect](external link)
  6. Arai K, Sakamoto R, Kubota D, Kondo T. Proteomic approach toward molecular backgrounds of drug resistance of osteosarcoma cells in spheroid culture system. Proteomics. 2013;13(15):2351-60. Epub 2013/ 05/ 29. PMID: 23712969.[PubMed](external link)
  7. Kubota D, Mukaihara K, Yoshida A, Suehara Y, Saito T, Okubo T, Gotoh M, Orita H, Tsuda H, Kaneko K, Kawai A, Kondo T. The prognostic value of Pfetin: a validation study in gastrointestinal stromal tumors using a commercially available antibody. Jpn J Clin Oncol. 2013;43(6):669-75. Epub 2013/ 04/ 27. PMID: 23619989.[PubMed](external link)
  8. Kimura K, Ojima H, Kubota D, Sakumoto M, Nakamura Y, Tomonaga T, Kosuge T, Kondo T. Proteomic identification of the macrophage-capping protein as a protein contributing to the malignant features of hepatocellular carcinoma. J Proteomics. 2013;78:362-73. Epub 2012/ 10/ 23. PMID: 23085225.[PubMed](external link)
  9. Huang C, Wang Y, Liu S, Ding G, Liu W, Zhou J, Kuang M, Ji Y, Kondo T, Fan J. Quantitative proteomic analysis identified Paraoxonase 1 as a novel serum biomarker for microvascular invasion in hepatocellular carcinoma. J Proteome Res. 2013;12(4):1838-46. Epub 2013/ 02/ 28. PMID: 23442176.[PubMed](external link)
  10. Haga A, Ogawara Y, Kubota D, Kitabayashi I, Murakami Y, Kondo T. Interactomic approach for evaluating nucleophosmin-binding proteins as biomarkers for Ewing's sarcoma. Electrophoresis. 2013;34(11):1670-8. Epub 2013/ 03/ 14. PMID: 23483572.[PubMed](external link)
  11. Yamamoto T, Nakayama K, Hirano H, Tomonaga T, Ishihama Y, Yamada T, Kondo T, Kodera Y, Sato Y, Araki N, Mamitsuka H, Goshima N. Integrated view of the human chromosome X-centric proteome project. J Proteome Res. 2013;12(1):58-61. Epub 2012/ 12/ 25. PMID: 23259409.[PubMed](external link)
  12. Sugihara Y, Taniguchi H, Kushima R, Tsuda H, Kubota D, Ichikawa H, Fujita S, Kondo T. Laser microdissection and two-dimensional difference gel electrophoresis reveal proteomic intra-tumor heterogeneity in colorectal cancer. J Proteomics. 2013;78:134-47. Epub 2012/ 11/ 28. PMID: 23178874.[PubMed](external link)
  13. Hasegawa T, Asanuma H, Ogino J, Hirohashi Y, Shinomura Y, Iwaki H, Kikuchi H, Kondo T. Use of potassium channel tetramerization domain-containing 12 as a biomarker for diagnosis and prognosis of gastrointestinal stromal tumor. Hum Pathol.2013;44(7):1271-7. Epub 2013/ 01/ 08. PMID: 23290008.[PubMed](external link)
  14. Kondo T, Suehara Y, Kikuta K, Kubota D, Tajima T, Mukaihara K, Ichikawa H, Kawai A. Proteomic approach toward personalized sarcoma treatment: Lessons from prognostic biomarker discovery in gastrointestinal stromal tumor. Proteomics Clin Appl. 2013;7(1-2):70-8. doi: 10.1002/prca.201200085. Review. PMID: 23281253. [PubMed]（external link）
  15. Suehara Y, Kohsaka S, Kubota D, Mukaihara K, Akaike K, Mineki R, Fujimura T, Kaneko K, Ladanyi M, Saito T, Kondo T. Proteomic Technologies to Develop Biomarkers and Functional Analyses. J Proteomics Bioinform. 2013, S3. doi: 10.4172/jpb.S3-001 [LongDom]（external link）

2012

  1. Uhlén M, Oksvold P, Älgenäs C, Hamsten C, Fagerberg L, Klevebring D, Lundberg E, Odeberg J, Pontén F, Kondo T, Sivertsson Å. Antibody-based protein profiling of the human chromosome 21. Mol Cell Proteomics. 2012;11(3):M111.013458. PMID: 22042635.[PubMed](external link)
  2. Sugihara Y, Taniguchi H, Kushima R, Tsuda H, Kubota D, Ichikawa H, Sakamoto K, Nakamura Y, Tomonaga T, Fujita S, Kondo T. Proteomic-based identification of the APC-binding protein EB1 as a candidate of novel tissue biomarker and therapeutic target for colorectal cancer. J Proteomics. 2012;75(17):5342-55. Epub 2012/ 06/ 28. PMID: 22735596.[PubMed](external link)
  3. Morofuji N, Ojima H, Onaya H, Okusaka T, Shimada K, Sakamoto Y, Esaki M, Nara S, Kosuge T, Asahina D, Ushigome M, Hiraoka N, Nagino M, Kondo T. Macrophage-capping protein as a tissue biomarker for prediction of response to gemcitabine treatment and prognosis in cholangiocarcinoma. J Proteomics. 2012;75(5):1577-89. PMID: 22155129.[PubMed](external link)
  4. Mimae T, Tsuta K, Maeshima A. M, Okada M, Asamura H, Kondo T, Tsuda H. Cathepsin D as a potential prognostic marker for lung adenocarcinoma. Pathol Res Pract. 2012;208(9):534-40. Epub 2012/ 07/ 25. PMID: 22824147.[PubMed](external link)
  5. Mimae T, Tsuta K, Kondo T, Nitta H, Grogan T. M, Okada M, Asamura H, Tsuda H. Protein expression and gene copy number changes of receptor tyrosine kinase in thymomas and thymic carcinomas. Ann Oncol. 2012;23(12):3129-37. Epub 2012/ 06/ 16. PMID: 22700994.[PubMed](external link)
  6. Kubota D, Okubo T, Saito T, Suehara Y, Yoshida A, Kikuta K, Tsuda H, Katai H, Shimada Y, Kaneko K, Kawai A, Kondo T. Validation study on Pfetin and ATP-dependent RNA helicase DDX39 as prognostic biomarkers in gastrointestinal stromal tumour. Jpn J Clin Oncol. 2012;42(8):730-41. Epub 2012/ 06/ 23. PMID: 22723667.[PubMed](external link)
  7. Kikuta K, Kubota D, Saito T, Orita H, Yoshida A, Tsuda H, Suehara Y, Katai H, Shimada Y, Toyama Y, Sato K, Kaneko K, Beppu Y, Murakami Y, Kawai A, Kondo T. Clinical proteomics identified ATP-dependent RNA helicase DDX39 as a novel biomarker to predict poor prognosis of patients with gastrointestinal stromal tumor. J Proteomics. 2012;75(4):1089-98. PMID: 22119546.[PubMed](external link)
  8. Ito A, Mimae T, Yamamoto Y. S, Hagiyama M, Nakanishi J, Ito M, Hosokawa Y, Okada M, Murakami Y, Kondo T. Novel application for pseudopodia proteomics using excimer laser ablation and two-dimensional difference gel electrophoresis. Lab Invest. 2012;92(9):1374-85. Epub 2012/ 07/ 04. PMID: 22751350.[PubMed](external link)
  9. Huang C, Ding G, Gu C, Zhou J, Kuang M, Ji Y, He Y, Kondo T, Fan J. Decreased Selenium-Binding Protein 1 Enhances Glutathione Peroxidase 1 Activity and Downregulates HIF-1α to Promote Hepatocellular Carcinoma Invasiveness. Clin Cancer Res. 2012;18(11):3042-53. PMID: 22512980.[PubMed](external link)
  10. Hosako M, Muto T, Nakamura Y, Tsuta K, Tochigi N, Tsuda H, Asamura H, Tomonaga T, Kawai A, Kondo T. Proteomic study of malignant pleural mesothelioma by laser microdissection and two-dimensional difference gel electrophoresis identified cathepsin D as a novel candidate for a differential diagnosis biomarker. J Proteomics. 2012;75(3):833-44. Epub 2011/ 11/ 05. PMID: 22051404.[PubMed](external link)
  11. Fujii K, Suzuki N, Ikeda K, Hamada T, Yamamoto T, Kondo T, Iwatsuki K. Proteomic study identified HSP 70 kDa protein 1A as a possible therapeutic target, in combination with histone deacetylase inhibitors, for lymphoid neoplasms. J Proteomics. 2012;75(4):1401-10. PMID: 22123078.[PubMed](external link)
  12. Vegvari A, Kondo T, Marshall J. G. Clinical proteomics. Int J Proteomics. 2012;2012:641491. doi: 10.1155/2012/641491. Epub 2012 Aug 15. PMID: 22934184; PMCID: PMC3426226. [PubMed]（external link）
  13. Suehara Y, Kubota D, Kikuta K, Kaneko K, Kawai A, Kondo T. Discovery of biomarkers for osteosarcoma by proteomics approaches. Sarcoma. 2012;2012時42分5636. Epub 2012 Nov 21. PMID: 23226966; PMCID: PMC3512344. [PubMed]（external link）
  14. Kondo T, Kubota D, Kawai A. Application of proteomics to soft tissue sarcomas. Int J Proteomics. 2012;2012:876401. doi: 10.1155/2012/876401. Epub 2012 Jun 19. PMID: 22778956; PMCID: PMC3388341. [PubMed]（external link）

2011

  1. Suehara Y, Tochigi N, Kubota D, Kikuta K, Nakayama R, Seki K, Yoshida A, Ichikawa H, Hasegawa T, Kaneko K, Chuman H, Beppu Y, Kawai A, Kondo T. Secernin-1 as a novel prognostic biomarker candidate of synovial sarcoma revealed by proteomics. J Proteomics. 2011;74(6):829-42. PMID: 21385630.[PubMed](external link)
  2. Muto T, Taniguchi H, Kushima R, Tsuda H, Yonemori H, Chen C, Sugihara Y, Sakamoto K, Kobori Y, Palmer H, Nakamura Y, Tomonaga T, Tanaka H, Mizushima H, Fujita S, Kondo T. Global expression study in colorectal cancer on proteins with alkaline isoelectric point by two-dimensional difference gel electrophoresis. J Proteomics. 2011;74(6):858-73. PMID: 21385629.[PubMed](external link)
  3. Mimae T, Tsuta K, Takahashi F, Yoshida A, Kondo T, Murakami Y, Okada M, Takeuchi M, Asamura H, Tsuda H. Steroid receptor expression in thymomas and thymic carcinomas. Cancer. 2011;117(19):4396-405. PMID: 21437890.[PubMed](external link)
  4. Kubota D, Orita H, Yoshida A, Gotoh M, Kanda T, Tsuda H, Hasegawa T, Katai H, Shimada Y, Kaneko K, Kawai A, Kondo T. Pfetin as a prognostic biomarker for gastrointestinal stromal tumor: validation study in multiple clinical facilities. Jpn J Clin Oncol. 2011;41(10):1194-202. PMID: 21903705.[PubMed](external link)
  5. Hagiwara T, Saito Y, Nakamura Y, Tomonaga T, Murakami Y, Kondo T. Combined use of a solid-phase hexapeptide ligand library with liquid chromatography and two-dimensional difference gel electrophoresis for intact plasma proteomics. Int J Proteomics. 2011;2011:739615. PMID: 22389768.[PubMed](external link)
  6. Gotoh M, Arai E, Wakai-Ushijima S, Hiraoka N, Kosuge T, Hosoda F, Shibata T, Kondo T, Yokoi S, Imoto I, Inazawa J, Kanai Y. Diagnosis and prognostication of ductal adenocarcinomas of the pancreas based on genome-wide DNA methylation profiling by bacterial artificial chromosome array-based methylated CpG island amplification. J Biomed Biotechnol. 2011;2011:780836. PMID: 21197409.[PubMed](external link)
  7. Arai E, Wakai-Ushijima S, Fujimoto H, Hosoda F, Shibata T, Kondo T, Yokoi S, Imoto I, Inazawa J, Hirohashi S, Kanai Y. Genome-wide DNA methylation profiles in renal tumors of various histological subtypes and non-tumorous renal tissues. Pathobiology. 2011;78(1):1-9. PMID: 21474971.[PubMed](external link)
  8. Misek D. E, Kondo T, Duncan M. W. Proteomics-based disease biomarkers. Int J Proteomics. 2011;2011:894618. doi: 10.1155/2011/894618. Epub 2011 Oct 30. PMID: 22110951; PMCID: PMC3205713. [PubMed]（external link）
  9. Kato H, Nishimura T, Ikeda N, Yamada T, Kondo T, Saijo N, Nishio K, Fujimoto J, Nomura M, Oda Y, Lindmark B, Maniwa J, Hibino H, Unno M, Ito T, Sawa Y, Tojo H, Egawa S, Edula G, Lopez M, Wigmore M, Inase N, Yoshizawa Y, Nomura F, Marko-Varga G. Developments for a growing Japanese patient population: facilitating new technologies for future health care. J Proteomics. 2011 May 16;74(6):759-64. doi: 10.1016/j.jprot.2010.12.006. Epub 2010 Dec 22. PMID: 21184850. [PubMed]（external link）

2010

  1. Shibata T, Kokubu A, Miyamoto M, Hosoda F, Gotoh M, Tsuta K, Asamura H, Matsuno Y, Kondo T, Imoto I, Inazawa J, Hirohashi S. DEK oncoprotein regulates transcriptional modifiers and sustains tumor initiation activity in high-grade neuroendocrine carcinoma of the lung. Oncogene. 2010;29(33):4671-81. PMID: 20543864.[PubMed](external link)
  2. Ojima H, Yoshikawa D, Ino Y, Shimizu H, Miyamoto M, Kokubu A, Hiraoka N, Morofuji N, Kondo T, Onaya H, Okusaka T, Shimada K, Sakamoto Y, Esaki M, Nara S, Kosuge T, Hirohashi S, Kanai Y, Shibata T. Establishment of six new human biliary tract carcinoma cell lines and identification of MAGEH1 as a candidate biomarker for predicting the efficacy of gemcitabine treatment. Cancer Sci. 2010;101(4):882-8. PMID: 20088962.[PubMed](external link)
  3. Nishiyama N, Arai E, Chihara Y, Fujimoto H, Hosoda F, Shibata T, Kondo T, Tsukamoto T, Yokoi S, Imoto I, Inazawa J, Hirohashi S, Kanai Y. Genome-wide DNA methylation profiles in urothelial carcinomas and urothelia at the precancerous stage. Cancer Sci. 2010;101(1):231-40. PMID: 19775289.[PubMed](external link)
  4. Kikuta K, Tochigi N, Saito S, Shimoda T, Morioka H, Toyama Y, Hosono A, Suehara Y, Beppu Y, Kawai A, Hirohashi S, Kondo T. Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics. Proteomics Clin Appl. 2010;4(5):560-7. PMID: 21137073.[PubMed](external link)
  5. Kikuta K, Gotoh M, Kanda T, Tochigi N, Shimoda T, Hasegawa T, Katai H, Shimada Y, Suehara Y, Kawai A, Hirohashi S, Kondo T. Pfetin as a prognostic biomarker in gastrointestinal stromal tumor: novel monoclonal antibody and external validation study in multiple clinical facilities. Jpn J Clin Oncol. 2010;40(1):60-72. PMID: 19815537.[PubMed](external link)
  6. Akishima-Fukasawa Y, Ino Y, Nakanishi Y, Miura A, Moriya Y, Kondo T, Kanai Y, Hirohashi S. Significance of PGP9.5 expression in cancer-associated fibroblasts for prognosis of colorectal carcinoma. Am J Clin Pathol. 2010;134(1):71-9. PMID: 20551269.[PubMed](external link)
  7. Kondo T. Cancer proteome-expression database: Genome Medicine Database of Japan Proteomics. Expert Rev Proteomics. 2010;7(1):21-7. doi: 10.1586/epr.09.87. Review. PMID: 20121473. [PubMed]（external link）

2009

  1. Yamada M, Fjii K, Koyama K, Hirohashi S, Kondo T. The proteomic profile of pancreatic cancer cell lines corresponding to carcinogenesis and metastasis. J Proteomics Bioinform. 2009;2(1):1-18. PMID: 1000057.[J Proteomics Bioinform](external link)
  2. Uemura N, Nakanishi Y, Kato H, Saito S, Nagino M, Hirohashi S, Kondo T. Transglutaminase 3 as a prognostic biomarker in esophageal cancer revealed by proteomics. Int J Cancer. 2009;124(9):2106-15. PMID: 19142970.[PubMed](external link)
  3. Uemura N, Nakanishi Y, Kato H, Nagino M, Hirohashi S, Kondo T. Antibody-based proteomics for esophageal cancer: Identification of proteins in the nuclear factor-kappaB pathway and mitotic checkpoint. Cancer Sci. 2009;100(9):1612-22. PMID: 19558549.[PubMed](external link)
  4. Tsuta K, Kato Y, Tochigi N, Hoshino T, Takeda Y, Hosako M, Maeshima A. M, Asamura H, Kondo T, Matsuno Y. Comparison of different clones (WT49 versus 6F-H2) of WT-1 antibodies for immunohistochemical diagnosis of malignant pleural mesothelioma. Appl Immunohistochem Mol Morphol. 2009;17(2):126-30. PMID: 19516197.[PubMed](external link)
  5. Suehara Y, Kikuta K, Nakayama R, Fujii K, Ichikawa H, Shibata T, Seki K, Hasegawa T, Gotoh M, Tochigi N, Shimoda T, Shimada Y, Sano T, Beppu Y, Kurosawa H, Hirohashi S, Kawai A, Kondo T. Anatomic site-specific proteomic signatures of gastrointestinal stromal tumors. Proteomics Clin Appl. 2009;3(5):584-96.[Wiley Online Library（PDF:440KB）](external link)
  6. Suehara Y, Kikuta K, Nakayama R, Fujii K, Ichikawa H, Shibata T, Seki K, Hasegawa T, Gotoh M, Tochigi N, Shimoda T, Shimada Y, Sano T, Beppu Y, Kurosawa H, Hirohashi S, Kawai A, Kondo T. GST-P1 as a hitological biomarker of synovial sarcoma revealed by proteomics. Proteomics Clin Appl. 2009;3(5):623-34.[Wiley Online Library](external link)
  7. Kosaihira S, Tsunehiro Y, Tsuta K, Tochigi N, Gemma A, Hirohashi S, Kondo T. Proteome expression database of lung adenocarcinoma: a segment of the genome medicine database of Japan proteomics. J Proteomics Bioinform. 2009;2(11):463-5. PMID: 1000106.[J Proteomics Bioinform](external link)
  8. Kondo T, Hirohashi S. Application of 2D-DIGE in cancer proteomics toward personalized medicine. Methods Mol Biol. 2009;577:135-54. PMID: 19718514.[PubMed](external link)
  9. Kikuta K, Tsunehiro Y, Yoshida A, Tochigi N, Hirohashi S, Kawai A, Kondo T. Proteome expression database of Ewing sarcoma: a segment of the genome medicine database of Japan proteomics. J Proteomics Bioinform. 2009;2(12):500-4. PMID: 1000112.[J Proteomics Bioinform](external link)
  10. Kikuta K, Tochigi N, Shimoda T, Yabe H, Morioka H, Toyama Y, Hosono A, Beppu Y, Kawai A, Hirohashi S, Kondo T. Nucleophosmin as a candidate prognostic biomarker of Ewing's sarcoma revealed by proteomics. Clin Cancer Res. 2009;15(8):2885-94. PMID: 19351769.[PubMed](external link)
  11. Harada C, Tajima H, Hirohashi S, Kondo T. Toward high performance western blotting using vacuum-driven system and laser scanner; comparison between two signal detection methods based on chemiluminescent and immunofluorescent imaging. J Electrophoresis. 2009;53(63).[J Electrophoresis（PDF:475KB）](external link)
  12. Arai E, Ushijima S, Gotoh M, Ojima H, Kosuge T, Hosoda F, Shibata T, Kondo T, Yokoi S, Imoto I, Inazawa J, Hirohashi S, Kanai Y. Genome-wide DNA methylation profiles in liver tissue at the precancerous stage and in hepatocellular carcinoma. Int J Cancer. 2009;125(12):2854-62. PMID: 19569176.[PubMed](external link)
  13. Arai E, Ushijima S, Fujimoto H, Hosoda F, Shibata T, Kondo T, Yokoi S, Imoto I, Inazawa J, Hirohashi S, Kanai Y. Genome-wide DNA methylation profiles in both precancerous conditions and clear cell renal cell carcinomas are correlated with malignant potential and patient outcome. Carcinogenesis. 2009;30(2):214-21. PMID: 19037089.[PubMed](external link)
  14. Kondo T, Hirohashi S. Application of 2D-DIGE in cancer proteomics toward personalized medicine. Methods Mol Biol. 2009;577:135-54. doi: 10.1007/978-1-60761-232-2_11. PubMed PMID: 19718514. [PubMed]（external link）

2008

  1. Suehara Y, Kondo T, Seki K, Shibata T, Fujii K, Gotoh M, Hasegawa T, Shimada Y, Sasako M, Shimoda T, Kurosawa H, Beppu Y, Kawai A, Hirohashi S. Pfetin as a prognostic biomarker of gastrointestinal stromal tumors revealed by proteomics. Clin Cancer Res. 2008;14(6):1707-17. PMID: 18347171.[PubMed](external link)
  2. Saito S, Ojima H, Ichikawa H, Hirohashi S, Kondo T. Molecular background of alpha-fetoprotein in liver cancer cells as revealed by global RNA expression analysis. Cancer Sci. 2008;99(12):2402-9. PMID: 19038010.[PubMed](external link)
  3. Orimo T, Ojima H, Hiraoka N, Saito S, Kosuge T, Kakisaka T, Yokoo H, Nakanishi K, Kamiyama T, Todo S, Hirohashi S, Kondo T. Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular carcinoma. Hepatology. 2008;48(6):1851-63. PMID: 18937283.[PubMed](external link)
  4. Arai E, Ushijima S, Tsuda H, Fujimoto H, Hosoda F, Shibata T, Kondo T, Imoto I, Inazawa J, Hirohashi S, Kanai Y. Genetic clustering of clear cell renal cell carcinoma based on array-comparative genomic hybridization: its association with DNA methylation alteration and patient outcome. Clin Cancer Res. 2008;14(17):5531-9. PMID: 18765545.[PubMed](external link)
  5. Kondo T. Tissue proteomics for cancer biomarker development: laser microdissection and 2D-DIGE. BMB Rep. 2008;Sep 30;41(9):626-34. Review. PMID: 18823585. [PubMed]（external link）
  6. Kondo T. Cancer proteomics for biomarker development. J Proteomics Bioinform. 2008;1(9):477-84.[LongDom]（external link）
  7. Kawai A, Kondo T, Suehara Y, Kikuta K, Hirohashi S. Global protein-expression analysis of bone and soft tissue sarcomas. Clin Orthop Relat Res. 2008 Sep;466(9):2099-106. doi: 10.1007/s11999-008-0330-4. Epub 2008 Jun 6. PMID: 18535868; PMCID: PMC2493021. [PubMed]（external link）

2007

  1. Katoh H, Ojima H, Kokubu A, Saito S, Kondo T, Kosuge T, Hosoda F, Imoto I, Inazawa J, Hirohashi S, Shibata T. Genetically distinct and clinically relevant classification of hepatocellular carcinoma: putative therapeutic targets. Gastroenterology. 2007 Nov;133(5):1475-86. PubMed PMID: 17983802.[PubMed](external link)
  2. Kakisaka T, Kondo T, Okano T, Fujii K, Honda K, Endo M, Tsuchida A, Aoki T, Itoi T, Moriyasu F, Yamada T, Kato H, Nishimura T, Todo S, Hirohashi S. Plasma proteomics of pancreatic cancer patients by multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis (2D-DIGE):up-regulation of leucine-rich alpha-2-glycoprotein in pancreatic cancer. J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 1;852(1-2):257-67. Epub2007 Feb 1. PubMed PMID: 17303479.[PubMed](external link)
  3. Yokoo H, Kondo T, Okano T, Nakanishi K, Sakamoto M, Kosuge T, Todo S, Hirohashi S. Protein expression associated with early intrahepatic recurrence of hepatocellular carcinoma after curative surgery. Cancer Sci. 2007 May;98(5):665-73. Epub 2007 Mar 28. PubMed PMID: 17391314.[PubMed](external link)
  4. Okano T, Kondo T, Fujii K, Nishimura T, Takano T, Ohe Y, Tsuta K, Matsuno Y, Gemma A, Kato H, Kudoh S, Hirohashi S. Proteomic signature corresponding to the response to gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma. Clin Cancer Res. 2007 Feb 1;13(3):799-805. PubMed PMID: 17289870.[PubMed](external link)
  5. Kondo T, HirohashiS.Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancerproteomics. Nat Protoc. 2007;1(6):2940-56. PubMed PMID: 17406554.[PubMed](external link)

2006

  1. Suehara Y, Kondo T, Fujii K, Hasegawa T, Kawai A, Seki K, Beppu Y, Nishimura T, Kurosawa H, Hirohashi S. Proteomic signatures corresponding to histological classification and grading of soft-tissue sarcomas. Proteomics. 2006;6(15):4402-9. PMID: 16807943.[PubMed](external link)
  2. Okano T, Kondo T, Kakisaka T, Fujii K, Yamada M, Kato H, Nishimura T, Gemma A, Kudoh S, Hirohashi S. Plasma proteomics of lung cancer by a linkage of multi-dimensional liquid chromatography and two-dimensional difference gel electrophoresis. Proteomics. 2006;6(13):3938-48. PMID: 16767791.[PubMed](external link)
  3. Hatakeyama H, Kondo T, Fujii K, Nakanishi Y, Kato H, Fukuda S, Hirohashi S. Protein clusters associated with carcinogenesis, histological differentiation and nodal metastasis in esophageal cancer. Proteomics. 2006;6(23):6300-16. PMID: 17133371.[PubMed](external link)
  4. Fujii K, Kondo T, Yokoo H, Okano T, Yamada M, Yamada T, Iwatsuki K, Hirohashi S. Database of two-dimensional polyacrylamide gel electrophoresis of proteins labeled with CyDye DIGE Fluor saturation dye. Proteomics. 2006;6(5):1640-53. PMID: 16429455.[PubMed](external link)
  5. Fujii K, Kondo T, Yamada M, Iwatsuki K, Hirohashi S. Toward a comprehensive quantitative proteome database: protein expression map of lymphoid neoplasms by 2-D DIGE and MS. Proteomics. 2006;6(17):4856-76. PMID: 16888764.[PubMed](external link)

2005

  1. Shibata T, Uryu S, Kokubu A, Hosoda F, Ohki M, Sakiyama T, Matsuno Y, Tsuchiya R, Kanai Y, Kondo T, Imoto I, Inazawa J, Hirohashi S. Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features. Clin Cancer Res. 2005;11(17):6177-85. PMID: 16144918.[PubMed](external link)
  2. Seike M, Kondo T, Fujii K, Okano T, Yamada T, Matsuno Y, Gemma A, Kudoh S, Hirohashi S. Proteomic signatures for histological types of lung cancer. Proteomics. 2005;5(11):2939-48. PMID: 15996008.[PubMed](external link)
  3. Naishiro Y, Yamada T, Idogawa M, Honda K, Takada M, Kondo T, Imai K, Hirohashi S. Morphological and transcriptional responses of untransformed intestinal epithelial cells to an oncogenic beta-catenin protein. Oncogene. 2005;24(19):3141-53. PMID: 15735679.[PubMed](external link)
  4. Mori Y, Kondo T, Yamada T, Tsuchida A, Aoki T, Hirohashi S. Two-dimensional electrophoresis database of fluorescence-labeled proteins of colon cancer cells. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;823(2):82-97. PMID: 16011914.[PubMed](external link)
  5. Katoh H, Shibata T, Kokubu A, Ojima H, Loukopoulos P, Kanai Y, Kosuge T, Fukayama M, Kondo T, Sakamoto M, Hosoda F, Ohki M, Imoto I, Inazawa J, Hirohashi S. Genetic profile of hepatocellular carcinoma revealed by array-based comparative genomic hybridization: identification of genetic indicators to predict patient outcome. J Hepatol. 2005;43(5):863-74. PMID: 16139920.[PubMed](external link)
  6. Fujii K, Kondo T, Yokoo H, Yamada T, Matsuno Y, Iwatsuki K, Hirohashi S. Protein expression pattern distinguishes different lymphoid neoplasms. Proteomics. 2005;5(16):4274-86. PMID: 16206328.[PubMed](external link)
  7. Fujii K, Kondo T, Yokoo H, Yamada T, Iwatsuki K, Hirohashi S. Proteomic study of human hepatocellular carcinoma using two-dimensional difference gel electrophoresis with saturation cysteine dye. Proteomics. 2005;5(5):1411-22. PMID: 15751005.[PubMed](external link)

2004

  1. Yokoo H, Kondo T, Fujii K, Yamada T, Todo S, Hirohashi S. Proteomic signature corresponding to alpha fetoprotein expression in liver cancer cells. Hepatology. 2004;40(3):609-17. PMID: 15349899.[PubMed](external link)
  2. Seike M, Kondo T, Fujii K, Yamada T, Gemma A, Kudoh S, Hirohashi S. Proteomic signature of human cancer cells. Proteomics. 2004;4(9):2776-88. PMID: 15352251.[PubMed](external link)
  3. Honda K, Yamada T, Seike M, Hayashida Y, Idogawa M, Kondo T, Ino Y, Hirohashi S. Alternative splice variant of actinin-4 in small cell lung cancer. Oncogene. 2004;23(30):5257-62. PMID: 15122314.[PubMed](external link)

2003

  1. Yamada T, Mori Y, Hayashi R, Takada M, Ino Y, Naishiro Y, Kondo T, Hirohashi S. Suppression of intestinal polyposis in Mdr1-deficient ApcMin/+ mice. Cancer Res. 2003;63(5):895-901. PMID: 12615699.[PubMed](external link)
  2. Seike M, Kondo T, Mori Y, Gemma A, Kudoh S, Sakamoto M, Yamada T, Hirohashi S. Proteomic analysis of intestinal epithelial cells expressing stabilized beta-catenin. Cancer Res. 2003;63(15):4641-7. PMID: 12907644.[PubMed](external link)
  3. Kondo T, Seike M, Mori Y, Fujii K, Yamada T, Hirohashi S. Application of sensitive fluorescent dyes in linkage of laser microdissection and two-dimensional gel electrophoresis as a cancer proteomic study tool. Proteomics. 2003;3(9):1758-66. PMID: 12973736.[PubMed](external link)
  • Our Research Focus